|Articles|March 1, 2017
March 2017: Big Data, Big Opportunity in Life Sciences
Author(s)LexisNexis
The big data transformation is poised to seep through the life sciences universe, promising to eliminate hundreds of billions of dollars of annual costs in the U.S. biopharmaceutical segment alone.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
AstraZeneca Shares Drop Following Wainua’s Failed Heart Disease Trial
2
U.S. Supreme Court Weighs Inducement Liability Beyond FDA Carve-Out Labels
3
Pharma M&A Roundup: Chemomab Therapeutics Enters Merger Agreement with Scipher Medicine, Teva and Polpharma Biologics Enter Global Licensing Agreement
4
Novartis to Layoff 322 NJ Employees: Report
5